Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apotex and Strides to merge Australia units

Executive Summary

Apotex and Strides Shasun have agreed in principle to merge their Australian businesses under a new entity, in a deal that will allow the combined company to become “the leading player in the Australian generic pharmaceutical market by both volume and revenue”. Strides will have a “controlling interest in the merged entity”, with the share-swap transaction subject to a final definitive agreement between the firms, as well as due diligence and regulatory approvals including from the Australian Competition and Consumer Commission (ACCC).

You may also be interested in...

Newly-Formed Arrotex Is Considering Further Deals

Following the formation of Australia’s Arrotex through the merger of Apotex Australia and former Strides unit Arrow Pharmaceuticals, CEO Dennis Bastas sets out the firm’s priorities as a central player in the Australian market, as well as longer-term plans including potential future deals and reaching beyond Australia and into south-east Asia, in an exclusive interview with Generics Bulletin.

Arrotex Formed As Strides-Apotex Merger Completes In Australia

Arrotex Australia Group has been formed in Australia following the completion of the merger between Strides’ Arrow and Apotex’ local unit.

Strides Sells Australian Business To Arrow-Apotex Merger

Strides Pharma Science has agreed to sell its entire Australian business, including its local Arrow unit, to the Arrow-Apotex merged entity known as ‘Arrotex’, as the firm concentrates its efforts in the US and Canada.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts